Pediatric Patients – Baqsimi

In a severe hypoglycemia emergency

Ready for rescue

The first and only glucagon with nasal administration

BAQSIMI^™ is indicated for the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates.

BAQSIMI is indicated in children 4 years and older. BAQSIMI has not been studied in patients less than 4 years of age.

BAQSIMI: designed with severe hypoglycemia treatment in mind

The first and only glucagon with nasal administration

Dry powder form of glucagon
Single use, pre-filled nasal device containing a 3 mg dose
Ready to use with no reconstitution or priming required
Ready to use with no reconstitution or priming
Does not need to be refrigerated, store up to 30°C (86°F) in the shrink-wrapped tube provided
Absorbed passively via the intranasal route—no inhalation required
BAQSIMI has a shelf life of 2 years from the date of manufacture
Each BAQSIMI device contains a single dose and is available as a 1-pack.

Do not remove shrink wrap or open the tube until ready to use.

Formulation invented in Canada

Continue to Pediatric Efficacy

Indications and Important Safety Information

Clinical use:
BAQSIMI has not been studied in pediatric patients less than 4 years old.

Limited clinical trial experience has not identified difference in responses between elderly (≥65 years of age) and younger patients.

Contraindications:

Hypersensitivity to glucagon or to any ingredient in the formulation or container
Pheochromocytoma
Insulinoma

Most serious warnings and precautions:
Lack of response: BAQSIMI should be given only in patients where impaired consciousness precludes oral carbohydrates. After intranasal administration of BAQSIMI, the patient will normally respond within 15 minutes. If the patient does not respond within 15 minutes, intravenous glucose must be administered as soon as IV access can be established.

States of starvation, adrenal insufficiency or chronic hypoglycemia: Because glucagon is of little or no help in these cases, intravenous glucose should be used for the treatment of hypoglycemia in these conditions.

Other relevant warnings and precautions:

Cardiovascular effects
Driving and operating machinery
Pheochromocytoma
Insulinoma
Sensitivity and resistance to glucagon
Pregnant women
Breast-feeding
Pediatrics (<4 years of age)
Geriatrics (≥65 years of age)
Use in patients with Type 2 diabetes taking sulfonylureas
Use with alcohol
Monitoring and laboratory tests

For more information:
Consult the Product Monograph at https://pdf.hres.ca/dpd_pm/00074561.PDF for additional important information relating to warnings and precautions, adverse reactions, drug interactions and dosing information which have not been discussed in this piece. The Product Monograph is also available by calling 1-800-423-4136.

Indications and Important Safety Information

Clinical use:
BAQSIMI has not been studied in pediatric patients less than 4 years old.

Limited clinical trial experience has not identified difference in responses between elderly (≥65 years of age) and younger patients.

Contraindications:

Hypersensitivity to glucagon or to any ingredient in the formulation or container
Pheochromocytoma
Insulinoma

Most serious warnings and precautions:
Lack of response: BAQSIMI should be given only in patients where impaired consciousness precludes oral carbohydrates. After intranasal administration of BAQSIMI, the patient will normally respond within 15 minutes. If the patient does not respond within 15 minutes, intravenous glucose must be administered as soon as IV access can be established.

States of starvation, adrenal insufficiency or chronic hypoglycemia: Because glucagon is of little or no help in these cases, intravenous glucose should be used for the treatment of hypoglycemia in these conditions.

Other relevant warnings and precautions:

Cardiovascular effects
Driving and operating machinery
Pheochromocytoma
Insulinoma
Sensitivity and resistance to glucagon
Pregnant women
Breast-feeding
Pediatrics (<4 years of age)
Geriatrics (≥65 years of age)
Use in patients with Type 2 diabetes taking sulfonylureas
Use with alcohol
Monitoring and laboratory tests

For more information:
Consult the Product Monograph at https://pdf.hres.ca/dpd_pm/00074561.PDF for additional important information relating to warnings and precautions, adverse reactions, drug interactions and dosing information which have not been discussed in this piece. The Product Monograph is also available by calling 1-800-423-4136.